Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001

Aug 26, 2021
Posted in: News, Investor updates

Home » Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001

Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001

Aug 26, 2021
Posted in: News, Investor updates

The document “Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001” was lodged with ASX on 26 August 2021.

Please click to review the full announcement at ASX.

The Unanswered Question in Prostate Cancer Diagnosis

September 24, 2026

Separating lethal disease from indolent disease remains the persistent difficulty, and molecular MRI may offer a way to see the difference. Prostate cancer is the

The Stock Network Interview – How MagSense® is moving towards Phase 2 clinical trials

September 4, 2026

Lel Smits from The Stock Network sat down with Imagion Biosystems’ Bob Proulx to discuss how the company is moving through the critical steps required

Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review

June 3, 2026

Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.

Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001

Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001

Related Articles

The Unanswered Question in Prostate Cancer Diagnosis

The Stock Network Interview – How MagSense® is moving towards Phase 2 clinical trials

Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review

Transforming medical imaging for early disease detection

About Imagion Biosystems

Contact us

Join our email list